Herein, we reported an NSCLC patient with leptomeningeal metastasis (LM) who acquired a novel EGFR-SEPT14 fusion during TKI resistance and showed promising responses to certain EGFR TKIs and intrathecal pemetrexed (IP). The gene discussed is EGFR; the disease is lymphangioma.